Discover how early CMC, process optimization, and formulation strategy drive scalable, commercially viable drugs.
- Maintenance formulation of small molecule ASC30 demonstrated an observed half-life of 75 days in participants with obesity in the U.S. Phase Ib study. - 75-day observed half-life supports ...
- The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) depot formulation (treatment formulation) of small molecule GLP-1 receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback